humulin 30/70 biosynthetic human 30% neutral 70% isophane insulin 100iu/ml injection multidose cartridge
eli lilly australia pty ltd - insulin, quantity: 100 iu/ml - injection, suspension - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide; protamine sulfate; metacresol; zinc oxide; glycerol; dibasic sodium phosphate heptahydrate; phenol - for the treatment of insulin dependent diabetic patients.
humulin 30/70 biosynthetic human 30% neutral 70% isophane insulin 100iu/ml injection 10ml vial
eli lilly australia pty ltd - insulin, quantity: 100 iu/ml - injection, suspension - excipient ingredients: zinc oxide; water for injections; phenol; sodium hydroxide; glycerol; metacresol; protamine sulfate; hydrochloric acid; dibasic sodium phosphate heptahydrate - for the treatment of insulin dependent diabetic patients.
lab series day rescue defense broad spectrum spf 35- avobenzone, homosalate, octisalate, and oxybenzone lotion
aramis inc. - avobenzone (unii: g63qqf2nox) (avobenzone - unii:g63qqf2nox), homosalate (unii: v06sv4m95s) (homosalate - unii:v06sv4m95s), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y) - - helps prevent sunburn - if used as directed with other sun protection measures (see directions ), decreases the risk of skin cancer and early skin aging caused by the sun
ilium tula injection
troy laboratories pty ltd - tulathromycin - parenteral liquid/solution/suspension - tulathromycin antibiotic active 100.0 mg/ml - antibiotic & related
iclusig 15 mg
incyte biosciences israel ltd, israel - ponatinib as hydrochloride - coated tablets - ponatinib as hydrochloride 15 mg - ponatinib - iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation • philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation.
iclusig 15 mg
incyte biosciences israel ltd, israel - ponatinib as hydrochloride - coated tablets - ponatinib as hydrochloride 15 mg - ponatinib - iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation • philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation.
iclusig 45 mg
incyte biosciences israel ltd, israel - ponatinib as hydrochloride - coated tablets - ponatinib as hydrochloride 45 mg - ponatinib - iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation • philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation.
iclusig 45 mg
incyte biosciences israel ltd, israel - ponatinib as hydrochloride - coated tablets - ponatinib as hydrochloride 45 mg - ponatinib - iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation • philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation.
biosense webster carto 3 system
johnson & johnson international (singapore) pte ltd - cardiovascular - the intended use of the carto® 3 system is catheter-based cardiac electrophysiological (ep) procedures. the carto® 3 system provides information about the electrical activity of the heart and about catheter location during the procedure. the system can be used on patients who are eligible for a conventional electrophysiological procedure.
biosense webster celsius fltr catheter
johnson & johnson international (singapore) pte ltd - cardiovascular - the celsius fltr catheter is indicated for cardiac electrophysiological mapping (stimulation and recording) and, when used in conjunction with a radiofrequency generator, for cardiac ablation.